Genovate Biotechnology Co., Ltd. (TPEX:4130)

Genovate Biotechnology Balance Sheet

Financials in millions TWD. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	352.36	169.04	221.6	180.03	194.17	198.44
Short-Term Investments	715.91	265.16	259.67	324.03	282.88	177.98
Trading Asset Securities	42.64	47.76	40.2	35.25	20	13
Cash & Short-Term Investments	1,111	481.96	521.47	539.3	497.05	389.42
Cash Growth	119.06%	-7.58%	-3.31%	8.50%	27.64%	-7.54%
Accounts Receivable	81.53	86.24	89.06	87.87	96.13	94.39
Other Receivables	2.4	1.32	1.4	1.28	27.77	0.77
Receivables	83.93	87.57	90.46	89.15	123.89	95.16
Inventory	138.95	143.83	145.87	139.64	145.86	139.94
Prepaid Expenses	12.54	5.94	7.34	3.39	14.79	10.38
Other Current Assets	0.01	0.01	0.31	0.29	0.28	0.02
Total Current Assets	1,346	719.3	765.45	771.77	781.88	634.93
Property, Plant & Equipment	404.62	410.42	393.95	392.12	403.29	409.6
Long-Term Investments	310.9	339.53	398.55	397.28	351.6	439.52
Other Intangible Assets	5.38	6.19	3.11	4.66	0.8	1.49
Other Long-Term Assets	31.24	30.93	29.16	34.62	26.87	29.97
Total Assets	2,098	1,506	1,590	1,600	1,564	1,516

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	26.95	29.97	40.28	32.87	45.91	35
Accrued Expenses	22.88	35.06	37.49	29.57	35.55	29.4
Current Portion of Leases	1.32	1.23	0.86	0.67	1.25	0.74
Current Income Taxes Payable	0.07	0.18	4.39	1.37	3.27	3.4
Current Unearned Revenue	2.02	1.79	1.96	4.9	4.73	4.03
Other Current Liabilities	53.02	57.1	51.5	48.36	41.12	38.05
Total Current Liabilities	106.26	125.32	136.48	117.73	131.84	110.61
Long-Term Leases	0.25	0.61	1.73	0.02	0.59	0.09
Pension & Post-Retirement Benefits	-	-	2.75	13.7	21.06	25.82
Other Long-Term Liabilities	0.12	0.12	0.12	0.24	0.12	0.12
Total Liabilities	106.62	126.05	141.08	131.69	153.6	136.65

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	1,379	1,149	1,127	1,094	1,094	1,100
Additional Paid-In Capital	631.58	210.71	210.66	210.56	210.51	208.93
Retained Earnings	120.47	131.77	152.63	177.79	202.18	167.97
Treasury Stock	-25.72	-25.72	-25.72	-	-	-63.03
Comprehensive Income & Other	-113.35	-85.32	-15.01	-13.34	-95.62	-35.04
Shareholders' Equity	1,992	1,380	1,449	1,469	1,411	1,379
Total Liabilities & Equity	2,098	1,506	1,590	1,600	1,564	1,516

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	1.57	1.84	2.58	0.68	1.84	0.83
Net Cash (Debt)	1,109	480.12	518.88	538.62	495.21	388.59
Net Cash Growth	119.86%	-7.47%	-3.66%	8.77%	27.44%	-7.29%
Net Cash Per Share	9.45	4.22	4.52	4.68	4.37	3.43
Filing Date Shares Outstanding	136.75	113.75	113.75	114.91	114.91	113.33
Total Common Shares Outstanding	136.75	113.75	113.75	114.91	114.91	113.33
Working Capital	1,240	593.98	628.97	654.05	650.04	524.32
Book Value Per Share	14.57	12.13	12.74	12.78	12.28	12.17
Tangible Book Value	1,986	1,374	1,446	1,464	1,410	1,377
Tangible Book Value Per Share	14.53	12.08	12.71	12.74	12.27	12.15
Land	140.74	140.74	140.74	140.74	140.74	140.74
Buildings	277.28	284.41	285.06	282.26	281.85	283.17
Machinery	130.4	136.25	168.27	158.6	180.44	160.91
Construction In Progress	38.13	36.53	2.49	1.88	0.61	0.41

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jul 25, 2026

Data Sources Report a data error